Business & Finance
Billionaire family offices boost investments in biotech startups
Wealth management firms for prominent figures like Stanley Druckenmiller, Jeff Bezos, and Bill Gates backed major funding rounds in August.
The short version
- Biotechnology startups made up roughly 20% of the 52 direct private company investments made by family offices in August, according to data from Fintrx.
- Major funding rounds included a $90 million Series C for Epicrispr Biotechnologies and a $188 million Series E for LifeMine Therapeutics.
- U.S. and European biopharma startups secured $12.6 billion during the first half of 2026, marking a five-year high in venture funding.
- Capital is increasingly concentrating in companies with clinical testing underway rather than early-stage ventures.
Key facts
- Family offices completed 52 direct private company investments in August, with biotechnology firms accounting for approximately 20% of those deals, according to Fintrx data.[CNBC]
- Stanley Druckenmiller's Duquesne Family Office participated in a $90 million Series C funding round for Epicrispr Biotechnologies, a startup developing gene therapy for facioscapulohumeral muscular dystrophy.[CNBC]
- Duquesne has invested in at least four life sciences or pharmaceutical companies in 2026, according to Fintrx.[CNBC]
- Jeff Bezos's family office and Bill Gates's Gates Frontier joined a $188 million Series E financing round for LifeMine Therapeutics, a company utilizing AI for genomic drug development.[CNBC]
- Biopharma startups across the United States and Europe raised $12.6 billion during the first half of 2026, reaching a five-year peak, based on analysis from Silicon Valley Bank and PitchBook.[CNBC]
- Silicon Valley Bank reported that investors are conducting fewer total deals overall, directing larger sums toward companies with active drug testing rather than early-stage startups.[CNBC]
What remains uncertain
- The efficacy and regulatory outcomes of experimental therapies, including LifeMine's transplant rejection drug and Epicrispr's gene therapy, remain dependent on ongoing clinical testing.[CNBC]